Danimer Scientific Announces $15 Million Registered Direct Offering
2024年3月21日 - 10:15AM
ビジネスワイヤ(英語)
Danimer Scientific, Inc. (NYSE: DNMR) (the “Company” or “Danimer
Scientific”), a leading next generation bioplastics company focused
on the development and production of biodegradable materials, today
announced that it has entered into a definitive agreement for the
purchase and sale of 15,000,000 shares of common stock (or common
stock equivalent in lieu thereof) at a purchase price of $1.00 per
share (or per common stock equivalent in lieu thereof) and
accompanying warrants to purchase up to an aggregate of 15,000,000
shares of common stock in a registered direct offering. The
warrants have an exercise price of $1.33 per share, will be
exercisable commencing six months from the date of issuance and
will expire five and one-half years following the date of issuance.
The closing of the offering is expected to occur on or about March
25, 2024, subject to the satisfaction of customary closing
conditions.
Roth Capital Partners is acting as the exclusive placement agent
for the offering.
The gross proceeds to the Company from the offering are expected
to be approximately $15 million before deducting placement agent
fees and other offering expenses payable by the Company. The
Company intends to use the net proceeds from the offering for
working capital and general corporate purposes.
The common stock (or common stock equivalent in lieu thereof)
and warrants described above are being offered by the Company
pursuant to a “shelf” registration statement on Form S-3 (File No.
333-267074) that was declared effective by the Securities and
Exchange Commission (the “SEC”) on September 7, 2022. The offering
is being made only by means of a prospectus, including a prospectus
supplement, forming a part of the effective registration statement.
A final prospectus supplement and accompanying prospectus relating
to the registered direct offering will be filed with the SEC.
Electronic copies of the final prospectus supplement and
accompanying prospectus relating to the registered direct offering
may be obtained, when available, by contacting Roth Capital
Partners, LLC 888 San Clemente Drive, Suite 400, Newport Beach, CA
92660, by phone at (800) 678-9147 or by accessing the SEC’s
website, www.sec.gov.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
jurisdiction.
About Danimer Scientific
Danimer is a pioneer in creating more sustainable, more natural
ways to make plastic products. For more than a decade, its
renewable and sustainable biopolymers have helped create plastic
products that are biodegradable and compostable and return to
nature instead of polluting our lands and waters. Danimer’s
technology can be found in a vast array of plastic end products
that people use every day. Applications for its biopolymers include
additives, aqueous coatings, fibers, filaments, films and
injection-molded articles, among others. Danimer holds more than
480 granted patents and pending patent applications in more than 20
countries for a range of manufacturing processes and biopolymer
formulations. For more information, visit
https://danimerscientific.com.
Forward‐Looking Statements
Please note that in this press release we may use words such as
“appears,” “anticipates,” “believes,” “plans,” “expects,”
“intends,” “future,” and similar expressions which constitute
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, without limitation, statements
regarding the Company’s estimated preliminary fourth quarter and
full-year 2023 results and our expectations for our future and
operational performance. Forward-looking statements are made based
on our expectations and beliefs concerning future events impacting
the Company and therefore involve a number of risks and
uncertainties. We caution that forward-looking statements are not
guarantees and that actual results could differ materially from
those expressed or implied in the forward-looking statements.
Potential risks and uncertainties that could cause the actual
results of operations or financial condition of the Company to
differ materially from those expressed or implied by
forward-looking statements in this release include, but are not
limited to, our ability to complete the equity offering on the
proposed terms, or at all; our expectations related to the use of
proceeds from the equity offering; the overall level of consumer
demand on our products; general economic conditions and other
factors affecting consumer confidence, preferences, and behavior;
disruption and volatility in the global currency, capital, and
credit markets; the financial strength of the Company’s customers;
the Company’s ability to implement its business strategy,
including, but not limited to, its ability to expand its production
facilities and plants to meet customer demand for its products and
the timing thereof; risks relating to the uncertainty of the
projected financial information with respect to the Company; the
ability of the Company to execute and integrate acquisitions;
changes in governmental regulation, legislation or public opinion
relating to our products; the Company’s exposure to product
liability or product warranty claims and other loss contingencies;
disruptions and other impacts to the Company’s business, as a
result of the COVID-19 global pandemic and government actions and
restrictive measures implemented in response; stability of the
Company’s manufacturing facilities and suppliers, as well as
consumer demand for our products, in light of disease epidemics and
health-related concerns such as the COVID-19 global pandemic; the
impact on our business, operations and financial results from the
ongoing conflict in Ukraine; the impact that global climate change
trends may have on the Company and its suppliers and customers; the
Company’s ability to protect patents, trademarks and other
intellectual property rights; any breaches of, or interruptions in,
our information systems; the ability of our information technology
systems or information security systems to operate effectively,
including as a result of security breaches, viruses, hackers,
malware, natural disasters, vendor business interruptions or other
causes; our ability to properly maintain, protect, repair or
upgrade our information technology systems or information security
systems, or problems with our transitioning to upgraded or
replacement systems; the impact of adverse publicity about the
Company and/or its brands, including without limitation, through
social media or in connection with brand damaging events and/or
public perception; fluctuations in the price, availability and
quality of raw materials and contracted products as well as foreign
currency fluctuations; our ability to utilize potential net
operating loss carryforwards; and changes in tax laws and
liabilities, tariffs, legal, regulatory, political and economic
risks. More information on potential factors that could affect the
Company’s financial results is included from time to time in the
Company’s public reports filed with the Securities and Exchange
Commission, including the Company’s Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.
All forward-looking statements included in this press release are
based upon information available to the Company as of the date of
this press release and speak only as of the date hereof. We assume
no obligation to update any forward-looking statements to reflect
events or circumstances after the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240320145675/en/
Investors Blake Chamblee Phone: 770-337-6570
ir@danimer.com Media Richard Ivey Phone: 229-254-7688
rivey@danimer.com
Danimer Scientific (NYSE:DNMR)
過去 株価チャート
から 5 2024 まで 6 2024
Danimer Scientific (NYSE:DNMR)
過去 株価チャート
から 6 2023 まで 6 2024